Audit: QRS - Anthocyanins for Health & Longevity

Audit conducted on 06/09/2026 04:08 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	84
Failed	0
N/A	9
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Spot-checked every populated span against the ER: protocol cells vs ER line 373/375/379, time cells vs line 426/161, benefit and risk items vs the ER tier headings, all ten monitoring rows and the six qualitative items transcribed from the ER table at lines 458-478.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Speculative tiers carry the ER wording (“Increased bleeding tendency with blood thinners”, “Blunting of training adaptations”); no hedge is dropped or added.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications keep the ER scope: “Pregnancy and breastfeeding at supplemental doses” matches ER line 351; “until stable” and “until repletion is complete” preserved.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefit-modifying and risk-modifying factors from ER lines 246-256 and 312-320 are not surfaced anywhere in the QRS.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, expert names, or brand names appear in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attribution appears in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER register: evidence-first, no promotional framing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Objective and data-driven; the at-a-glance names what is best supported without overstatement.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Presents ER-sourced gates and protocol figures without instructing.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No clinical advice; the footer disclaimer is the fixed template text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Content is presented as ER-derived facts and schedules, not recommendations.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun anywhere in the file (verified).
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms carry ER glosses: “INR (clotting-time ratio)”, “blood thinners”, “blood-pressure drugs”, “painkillers”.
2.8	Information is presented in a concise and very compact manner	🟢	Every cell is a condensed phrase; no elaboration or mechanistic prose beyond the single-clause protocol subs.
2.9	It DOES NOT address the reader directly	🟢	No direct address (verified).
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content is pitched at readers acting on biomarkers and a supplement protocol.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Protocol, monitoring cadence and 14-day procedure pause assume willingness to follow effortful protocols.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Not written for a general audience; assumes lipid, HbA1c and ferritin literacy.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance and benefits explicitly flag that the effect is concentrated in people whose readings are already abnormal.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear (verified).
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal terms lead each interaction (“Anticoagulants and antiplatelet drugs”, “Antihypertensives”, “Over-the-counter analgesics”) with the ER gloss in parentheses.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and the Marker/Target/Why column headers match the template byte for byte.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template data-qrs-var spans are present; marker_# and qualitative_item_# expand to marker_1-10 and qualitative_item_1-6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Diff against the template shows only metadata, <title> and variable content changed; website="evidence_review", website="audit" and website="full_review" spans are untouched.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No ER section relevant to the QRS is empty or uses empty-state phrasing; the ER High-risk tier carries an explanatory paragraph and is handled under 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels are the ER bold labels verbatim: “Standard supplemental dose”, “Best time of day”, “Food-first alternative” (ER lines 373, 379, 375).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time labels use the ER’s own wording (“Artery widening”, “Lipid and glucose changes”, cognitive change) and marker names are the ER table names verbatim.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji characters in the file (verified).
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is condensed to headings and single clauses; no section carries ER elaboration, effect sizes, or citations onto the sheet.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	The metadata comment spans lines 2-14, immediately after <!doctype html> and before any other content.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML opens at line 3 and closes at line 13; the “QRS — Metadata” text before the opening --- is not parsed.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Inside an HTML comment; not surfaced by any element on the sheet.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which is required because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: anthocyanins_2026-0906-0002_Opus_ER.md matches the source ER.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 matches the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0906-0353 is in YYYY-MMDD-HHMM form.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	Single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	Nickname plus version number, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: anthocyanins_2026-0906-0002_Opus_QRS.html matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Confirmed again across the full block; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., &amp; for &)	🟢	<title>Anthocyanins for Health &amp; Longevity - Quick Reference Sheet</title>, with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., &amp; for &)	🟢	header_topic is “Anthocyanins for Health & Longevity”, matching the ER canonical_topic.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/06/2026 is qrs_creation_date 2026-0906-0353 in MM/DD/YYYY form.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	header_subline_model is “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only the title and the template subline; no badge, AKA line, or audit stamp.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses all four Conclusion paragraphs (ER lines 500-506) into the pigment/metabolite mechanism, the best-supported outcomes, the harm profile, and the realistic cautions.
7.2	[at_a_glance] is no longer than 60 words	🟢	57 words (counted).
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Sentence 1 maps to ER line 500, sentence 2 to line 502, sentences 3-4 to line 504.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “wider arteries”, “better cholesterol readings”, “lower blood sugar”, “digestive upset” replace the technical terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, or sample sizes.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No effect sizes, relative risks, or statistics.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All five items trace to the “Populations who should avoid anthocyanins” list at ER lines 347-351.
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five ER avoid-populations are represented, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Each item is its own <li> inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Trailing rationale stripped, e.g. ER “because of the theoretical additive platelet effect” and “food-level intake is not implicated” are dropped; no dash-trailing clause remains.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Qualifiers preserved: “within 14 days”, “persistently above 3.0, until stable”, “ferritin below 15 ng/mL, until repletion is complete”, the four source species, “at supplemental doses”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The section is populated, and the ER does identify avoid-populations.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty; five contraindications are present.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All ten items trace to the ER interaction bullets at lines 325-343.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All ten ER interactions are carried; none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Each item is its own <li> inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Caution/Monitor verdicts, mechanisms, consequences and mitigations are all stripped; the ER em-dash inside the first three parentheticals is normalised to a colon rather than carried with trailing text.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every ER example drug list is preserved in full, including the four-drug anticoagulant, three-drug antihypertensive and five-item supplement lists.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The section is populated, and the ER does identify interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty; ten key interactions are present.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	Drawn from the ER Therapeutic Protocol section (lines 373-393).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, timing and the food-first route are the three implementation decisions a reader must make first.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section supplies more than three distinct actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine used cells carry ER content; action_2 is verbatim from ER line 379.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER supplies exactly three time-to-effect aspects at line 426; all three are used.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered artery widening (High benefit), lipid and glucose (High), cognitive (Low), matching the ER benefit tiers.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine used cells carry ER content; the 8-24 week trial-length note traces to ER line 161.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER Practical Considerations section provides time-to-effect information (line 426).

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every item is an ER Expected Benefits heading, in ER order within each tier.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four tier spans are populated.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER headings, lowercased; no magnitudes, mechanisms, or “Conflicted” annotations carried.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers (High, Medium, Low, Speculative) carry items in the ER Expected Benefits section.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every item is an ER Potential Risks & Side Effects heading, in ER order within each tier.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four tier spans are present; risks_high is retained but hidden.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items are the bare ER headings, lowercased; frequencies and mechanisms stripped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parenthetical content appears in any risk item.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states no risk reaches High (line 265), and risks_high carries style="display: none" rather than empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Drawn from the ER Monitoring Protocol & Defining Success table (lines 458-469).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All ten ER biomarkers are present in ER order, with targets and rationales transcribed.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Cadence carries the full ER schedule from lines 456: 12 weeks, 24 weeks, every 6-12 months, plus the weekly glucose and 4-week standing blood-pressure conditions.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Drawn from the qualitative marker list at ER lines 473-478.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers are present, verbatim and in ER order.

Issues 06/09/2026 04:08

Pass rate 100.00%. No issues found.

Issues 06/09/2026 04:00

1. 1.4 — Monitoring fact placed in Time to Effect: [time_2_sub] at line 512 reads “Panel repeated at 12 weeks”, which is monitoring cadence lifted from the ER Monitoring Protocol & Defining Success section (ER line 456) rather than a time-to-effect fact from ER line 426.
2. 2.7 — Unexpanded clinical acronyms: [marker_2_why] at line 671 uses “CETP” and [stop_items] at line 567 uses “INR”, neither expanded anywhere in the QRS, although the ER glosses both (ER lines 131 and 325).

Fixes 06/09/2026 04:00

1. 1.4 — Monitoring fact moved out of Time to Effect: Replaced [time_2_sub] “Panel repeated at 12 weeks” with “Trials ran 8–24 weeks at 320 mg daily”, a time-to-effect fact drawn from the ER Expected Benefits magnitude line rather than the ER Monitoring cadence.
2. 2.7 — CETP acronym expanded: Changed [marker_2_why] from “Rises via CETP inhibition” to “Rises via blocked cholesterol transfer between lipoprotein particles”, using the ER’s own plain-language gloss of CETP.
3. 2.7 — INR acronym glossed: Added the ER’s plain-language gloss to the warfarin contraindication, from “unstable INR” to “unstable INR (clotting-time ratio)”, keeping the 3.0 threshold and the “until stable” window intact.